U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07157306) titled 'Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma' on Aug. 14.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Study Start Date: Sept. 10
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Intervention:
DRUG: Gecacitinib Combined With Donafenib and PD-1 Inhibitor
Subjects were enrolled and started receiving treatment with Gecacitinib (100mg, Bid, po) for 7 consecutive days; there...